Optimer Pharmaceuticals, Inc. Completes Enrollment in OPT-80 Phase 3 Clinical Trial in Patients with Clostridium difficile Infection

SAN DIEGO--(BUSINESS WIRE)--Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) today announced that the company has completed enrollment in the first of two pivotal Phase 3 clinical trials evaluating the safety and efficacy of OPT-80 for the treatment of Clostridium difficile infection, or CDI.